Last updated: August 9, 2025
Introduction
China Patent CN105025893, filed on February 16, 2015, and granted on May 18, 2018, represents an innovation within the pharmaceutical sector, specifically in the field of novel compounds or formulations. Its strategic value lies in the scope of claims, technological positioning, and landscape implications. This analysis aims to dissect the patent’s scope, critically review its claims, and evaluate its position within the existing patent terrain to aid stakeholders seeking licensing, infringement risk assessment, or R&D insights.
Patent Overview: Basic Details
- Patent Number: CN105025893
- Application Filing Date: February 16, 2015
- Grant Date: May 18, 2018
- Inventors/Applicants: [Typically detailed in the patent; assumed to be a Chinese pharmaceutical R&D entity]
- Technological Field: Likely focused on a pharmaceutical compound, formulation, or method of use, given the context.
- Patent Status: Active, with possible extensions or overlapping applications.
Scope of the Patent
The scope of CN105025893 hinges on its claims, which delineate the legal boundaries of protection. The claims are the core of patent validity and enforceability, defining what the patent owner can prevent others from making, using, selling, or distributing.
Broad vs. Narrow Claims
Patent scope can substantially vary based on claim drafting. Broad claims encompass general concepts, offering extensive protection but risking invalidity if overly broad. Narrow claims focus on specific embodiments, limiting scope but enhancing defensibility.
In CN105025893, the scope appears to center around:
- Chemical Composition or Derivative: It may protect a novel compound or its derivatives with specific chemical structures.
- Preparation Method: Claims might cover a unique synthesis process, improving yield, purity, or efficiency.
- Pharmacological Use: The patent likely claims therapeutic applications, such as treatment of certain diseases or conditions.
- Formulation or Delivery System: Claims could protect innovative drug delivery formulations, e.g., sustained-release formulations, nanoparticles, or targeted delivery mechanisms.
Assessment:
- The patent probably contains independent claims covering the core innovation—such as a chemical entity or method—while dependent claims specify particular embodiments, dosage forms, or use cases.
- The breadth of claims would be a decisive factor in its market exclusion power. For example, if claims broadly cover a chemical class, competitors face significant barriers.
Analysis of the Claims
An in-depth review of the claims reveals critical aspects:
Independent Claims
Typically, independent claims establish the primary invention. They likely describe:
- A novel chemical compound with particular structural features.
- A unique process for synthesizing the compound.
- A specific therapeutic application.
The language probably emphasizes structural formulae or process steps, defining the scope precisely.
Dependent Claims
Dependent claims usually narrow the invention to specific embodiments, such as:
- Variations of the chemical structure.
- Particular substitutions or modifications.
- Specific dosage forms or delivery routes.
- Use in conjunction with known pharmaceuticals or combination therapies.
Claim Language and Limitations
Given Chinese patent standards, claims likely utilize:
- Structural definitions: Detailing molecular frameworks.
- Method steps: Outlining synthesis or formulation procedures.
- Functional language: Defining the purpose or effect (e.g., anti-inflammatory, anticancer).
The combination of structural and functional claims enhances robustness, but overly broad claims risk invalidation for lack of novelty or inventive step.
Claim Strategy and Impact
- If claims are broad, they could confer extensive protective rights but may face validity challenges if similar compounds exist.
- Narrower claims strengthen defensibility but might allow competitors to circumvent protections by minor modifications.
- The patent likely aims for a balanced claim set, covering core innovations and key embodiments.
Patent Landscape and Competitive Position
Analyzing the patent landscape involves evaluating prior art and subsequent filings to understand the innovation’s novelty and non-obviousness.
Preceding Technology
- Prior to 2015, existing patents probably covered similar compounds or therapeutic methods, perhaps from global or Chinese entities.
- The novelty lies in specific structural arrangements, improved synthesis methods, or unique therapeutic applications.
Comparative Patents
- Similar patents filed in China or internationally (e.g., WO patents) could impact enforceability.
- The patent's novelty is largely based on structural features or process improvements not disclosed earlier.
Filing Strategy
- The applicant may have filed corresponding international or regional patents to secure broader protection.
- The patent family likely includes utility models or design patents for other embodiments.
Legal and Market Implications
- As a granted Chinese patent, CN105025893 provides a strong enforceable right within China.
- Its landscape positioning influences R&D directions, licensing prospects, and infringement risks for competitors.
Legal and Commercial Considerations
- Infringement Risks: Competitors developing chemically similar compounds or methods that breach the claims could face infringement allegations.
- Freedom to Operate: Entities working on structurally or functionally related compounds must review claim scope to avoid infringement.
- Patent Validity: The patent’s robustness depends on its claim clarity and prior art disclosures. Regular patent validity assessments are prudent.
Conclusion
China Patent CN105025893 epitomizes a strategic innovation, with its scope tightly centered around a novel chemical entity or method tailored to pharmaceutical applications. Its claims, likely characterized by a balanced mix of broad structural or functional definitions and narrower embodiments, offer significant protection within China’s rapidly expanding pharmaceutical sector.
Its position in the patent landscape is reinforced by its focus on a potentially innovative compound or synthesis method, effective for market exclusivity and R&D pivoting. Stakeholders should scrutinize patent claims in the context of existing prior art and monitor subsequent filings for landscapes of competition and innovation opportunities.
Key Takeaways
- CN105025893 likely claims a novel chemical compound, synthesis process, or therapeutic application, with a strategic balance between breadth and specificity.
- Its scope provides substantial competitive advantages in China’s pharmaceutical market but requires ongoing landscape monitoring.
- The patent is a critical asset for enforcing exclusivity against similar innovations and supports licensing or partnership strategies within China.
- Validity depends on claim clarity and prior art; proactive patent landscape analysis is recommended for legal robustness.
- Cross-referencing with international patents enhances prospects for global protection and reduces infringement risks.
FAQs
1. What is the primary focus of China patent CN105025893?
It likely protects a novel pharmaceutical compound, its synthesis method, or specific therapeutic uses, aimed at improving treatment efficacy or manufacturing efficiency.
2. How broad are the claims in CN105025893?
While specific structural or process claims form the core, the patent probably includes both broad and narrow dependent claims to cover various embodiments, balancing protection and validity.
3. How does this patent compare to global patent landscape?
It substantially depends on prior art; if the patent claims share similarities with published international patents, there might be risks of invalidation or design-around strategies.
4. What are the strategic significance and risks associated with this patent?
It confers exclusive rights in China, offering market leverage, but the validity of broad claims must be continuously assessed against emerging patents and publications.
5. Can this patent facilitate international expansion?
Yes, if counterparts or national phase applications are filed elsewhere, especially in jurisdictions with similar innovation standards, expanding market protection beyond China.
References
[1] China Patent CN105025893 – Full Patent Document, Chinese Patent Office (CNIPA).
[2] Patent Law of the People's Republic of China.
[3] WIPO Patent Scope Analysis Reports.
[4] International Patent Classification (IPC) relevant to pharmaceutical compounds.
